Castle Biosciences, Inc. (CSTL)
CSTLNASDAQ-GMMedical Specialities
$34.38
0.0000 (0.00%) today
Pre-market, Nov 9, 4:00 PM ET
- Market cap
- $1.06bn
- P/E
- –
- EPS, last 4 quarters
- $-0.7700
- Dividend yield
- –
- Day range
- –
- 52-week range
- $17.72 to $44.28
- Average volume
- 370.6k
- Previous close
- $34.38
Analysts
6 coveringBuy6 buy, 0 hold, 0 sell
Targets a year out average $48.29, +40.5% from here
Earnings
next estimate $-0.3600Next report
Dec 2025
+65.2%
Mar 2026
+12.5%
Jun 2026
+84.1%
Sep 2026
+65.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $87.01m | $83.68m | $103.55m | $102.89m |
| Gross profit | $68.69m | $63.15m | $79.85m | $78.97m |
| Operating income | -$3.83m | -$18.41m | -$3.07m | -$2.73m |
| Net income | -$2.33m | -$14.52m | -$2.06m | -$4.10m |
Last four quarters: revenue $377.13m, margin -6.1%, free cash flow $3.96m
News
8 latest- Castle Bio (CSTL) Q3 2026 Earnings Call TranscriptThe Motley Fool · 4 days ago
- What Castle Biosciences (CSTL) Said on Its Q3 Earnings CallMarketBeat · 4 days ago
- Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Beats Revenue EstimatesZacks · 5 days ago
- Castle Biosciences Reports TissueCypher Changed Management In 90% Of NDBE Patients RTTNews · Sep 28, 2026
- Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know Zacks · Aug 28, 2026
- Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?Zacks · Aug 25, 2026
- Castle Biosciences Approved For Dual Listing On Nasdaq Texas RTTNews · Aug 17, 2026
- Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain TractionMarketBeat · Aug 13, 2026
The company
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes. We put people first-empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning.
- Sector
- Health Care
- Industry
- Medical Specialities
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- castlebiosciences.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.